Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer
Authors:
- G.E. AdamsGAG.E. Adams
- I.J. StratfordISI.J. Stratford
- 1 January 1986
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 35 (1) , 71-76
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Sensitization of cancer chemotherapeutic agents by nitroheterocyclicsBiochemical Pharmacology, 1986
- RSU 1069, a nitroimidazole containing an aziridine groupBiochemical Pharmacology, 1986
- The clinical testing of Ro 03-8799—Pharmacokinetics, toxicology, tissue and tumor concentrationsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1984
- RSU 1069, a 2-nitroimidazole containing an alkylating group: High efficiency as a radio- and chemosensitizer in vitro and in vivoInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1984
- Radiation sensitization and chemopotentiation: Rsu 1069, a compound more efficient than misonidazole in vitro and in vivoBritish Journal of Cancer, 1984
- Enhancement of nitrosourea cytotoxicity by misonidazole in vitro: Correlation with carbamoylating potentialBritish Journal of Cancer, 1984
- Potentiation of melphalan activity against a murine tumour by nitroimidazole compoundsBritish Journal of Cancer, 1982
- Ascorbate-enhanced Cytotoxicity of misonidazoleNature, 1978
- Cytotoxicity of Ro-07-0582; enhancement by hyperthermia and protection by cysteamineBritish Journal of Cancer, 1977
- Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitroBritish Journal of Cancer, 1977